HR-Positive Breast Cancer: Workflow Integration and Clinical Decision Triggers for ESR1 Testing

This segment explores how ESR1 mutation testing may be integrated into clinical workflows for hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky raises questions about whether electronic medical record systems will incorporate prompts or best practice alerts to guide testing decisions.

Dr. Lisa Raff emphasizes that embedding testing into treatment regimens may be more practical than relying on alert-based systems, given the risk of alert fatigue among clinicians. She highlights the importance of designing workflows that support timely testing while minimizing burden on providers.

Dr. Hope S. Rugo underscores the need for clinical context when deciding when to test, noting that symptomatic progression may be a more appropriate trigger than routine testing in asymptomatic patients. She also highlights the absence of definitive survival data and the availability of multiple treatment options. Overall, this segment highlights the complexity of integrating biomarker testing into real-world practice.